for people ages 2 years and up (full criteria)
at Los Angeles, California and other locations
study started
completion around
Principal Investigator
by Shaun Hussain



This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

Official Title

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome


This is an international, multicenter, open-label, long-term safety study of ZX008 in patients with epileptic encephalopathy, including Dravet syndrome or Lennox-Gastaut syndrome. Subjects eligible for participation are those with Dravet syndrome who are currently enrolled in Study ZX008-1503, or those with Lennox-Gastaut syndrome who have successfully completed Study ZX008-1601-Part 2, and are candidates for continued treatment with ZX008 for an extended period of time, or those with Dravet syndrome, Lennox-Gastaut syndrome, or another epileptic encephalopathy who have completed participation in another Zogenix-sponsored study and have been invited to participate in this study.


Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy, Brain Diseases, Epilepsy, Myoclonic Epilepsies, Syndrome, Fenfluramine, ZX008 (Fenfluramine Hydrochloride)


You can join if…

Open to people ages 2 years and up

  • Male or nonpregnant, nonlactating female
  • Satisfactory completion of a core study
  • Has a rare seizure disorder, such as epileptic encephalopathy and has successfully completed another Zogenix-sponsored clinical trials with ZX008
  • Subject's caregiver is willing and able to be compliant with study procedures, visit schedule and study drug accountability

You CAN'T join if...

  • Current cardiac valvulopathy or pulmonary hypertension that is clinically significant
  • Moderate or severe hepatic impairment
  • Receiving monoamine oxidase inhibitors, serotonin agonists, serotonin antagonists, and serotonin reuptake inhibitors within 14 days of receiving ZX008


  • Ep0215 144
    Los Angeles California 90095 United States
  • Ep0215 108
    San Diego California 92123 United States

Lead Scientist at UCLA

  • Shaun Hussain
    Hs Clinical Professor, Pediatrics, Medicine. Authored (or co-authored) 38 research publications


in progress, not accepting new patients
Start Date
Completion Date
Zogenix, Inc.
Phase 3 research study
Study Type
About 412 people participating
Last Updated